Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clonetics is a premier brand specializing in the production of high-quality primary cells and optimized cell culture media, currently operating as a key division of Lonza. Originally established as an independent corporation, it pioneered the commercialization of standardized human cell systems, providing researchers with a more biologically relevant alternative to immortalized cell lines. The company's portfolio includes a wide range of human and animal primary cells, such as endothelial, epithelial, and myogenic cells, along with specialized BulletKit media systems. These products are essential tools in drug discovery, toxicity testing, and regenerative medicine research. Clonetics continues to be recognized as a gold standard in the life sciences industry for primary cell culture and standardized research models.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Clonetics.